122 related articles for article (PubMed ID: 10780811)
1. SR 141716A, a CB1 cannabinoid receptor antagonist, potentiates the locomotor stimulant effects of amphetamine and apomorphine.
Masserano JM; Karoum F; Wyatt RJ
Behav Pharmacol; 1999 Jul; 10(4):429-32. PubMed ID: 10780811
[TBL] [Abstract][Full Text] [Related]
2. The CB1 cannabinoid receptor antagonist SR 141716A affects A9 dopamine neuronal activity in the rat.
Gueudet C; Santucci V; Rinaldi-Carmona M; Soubrié P; Le Fur G
Neuroreport; 1995 Jul; 6(10):1421-5. PubMed ID: 7488739
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute D-amphetamine.
Polissidis A; Chouliara O; Galanopoulos A; Naxakis G; Papahatjis D; Papadopoulou-Daifoti Z; Antoniou K
Behav Brain Res; 2014 Aug; 270():261-9. PubMed ID: 24867330
[TBL] [Abstract][Full Text] [Related]
4. SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study.
Bass CE; Griffin G; Grier M; Mahadevan A; Razdan RK; Martin BR
Pharmacol Biochem Behav; 2002 Dec; 74(1):31-40. PubMed ID: 12376150
[TBL] [Abstract][Full Text] [Related]
5. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
6. SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats.
Costa B; Vailati S; Colleoni M
Behav Pharmacol; 1999 May; 10(3):327-31. PubMed ID: 10780247
[TBL] [Abstract][Full Text] [Related]
7. Previous exposure to delta9-tetrahydrocannibinol enhances locomotor responding to but not self-administration of amphetamine.
Cortright JJ; Lorrain DS; Beeler JA; Tang WJ; Vezina P
J Pharmacol Exp Ther; 2011 Jun; 337(3):724-33. PubMed ID: 21389094
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of amphetamine- and apomorphine-induced behavioural effects by neuropeptide Y Y(1) receptor antagonist BIBO 3304.
Kask A; Harro J
Neuropharmacology; 2000 Apr; 39(7):1292-302. PubMed ID: 10760371
[TBL] [Abstract][Full Text] [Related]
9. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat.
Martin RS; Secchi RL; Sung E; Lemaire M; Bonhaus DW; Hedley LR; Lowe DA
Psychopharmacology (Berl); 2003 Jan; 165(2):128-35. PubMed ID: 12404071
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of penile erection and yawning responses to apomorphine by cannabinoid receptor antagonist in rats.
da Silva GE; Fernandes MS; Takahashi RN
Neurosci Lett; 2003 Sep; 349(1):49-52. PubMed ID: 12946584
[TBL] [Abstract][Full Text] [Related]
11. Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils.
Poncelet M; Barnouin MC; Brelière JC; Le Fur G; Soubrié P
Psychopharmacology (Berl); 1999 May; 144(2):144-50. PubMed ID: 10394995
[TBL] [Abstract][Full Text] [Related]
12. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
Darmani NA
Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
[TBL] [Abstract][Full Text] [Related]
13. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat.
Navarro M; Hernández E; Muñoz RM; del Arco I; Villanúa MA; Carrera MR; Rodríguez de Fonseca F
Neuroreport; 1997 Jan; 8(2):491-6. PubMed ID: 9080435
[TBL] [Abstract][Full Text] [Related]
14. Analogs of SR-141716A (Rimonabant) alter d-amphetamine-evoked [3H] dopamine overflow from preloaded striatal slices and amphetamine-induced hyperactivity.
Miller DK; Rodvelt KR; Constales C; Putnam WC
Life Sci; 2007 Jun; 81(1):63-71. PubMed ID: 17532007
[TBL] [Abstract][Full Text] [Related]
15. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats.
Solinas M; Panlilio LV; Antoniou K; Pappas LA; Goldberg SR
J Pharmacol Exp Ther; 2003 Jul; 306(1):93-102. PubMed ID: 12660305
[TBL] [Abstract][Full Text] [Related]
16. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
Darmani NA
Pharmacol Biochem Behav; 2001; 69(1-2):239-49. PubMed ID: 11420092
[TBL] [Abstract][Full Text] [Related]
17. Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.
Rinaldi-Carmona M; Pialot F; Congy C; Redon E; Barth F; Bachy A; Brelière JC; Soubrié P; Le Fur G
Life Sci; 1996; 58(15):1239-47. PubMed ID: 8614277
[TBL] [Abstract][Full Text] [Related]
18. Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited.
Järbe TU; Andrzejewski ME; DiPatrizio NV
Pharmacol Biochem Behav; 2002 Nov; 73(4):911-9. PubMed ID: 12213538
[TBL] [Abstract][Full Text] [Related]
19. WIN-55,212-2 and SR-141716A alter nicotine-induced changes in locomotor activity, but do not alter nicotine-evoked [3H]dopamine release.
Rodvelt KR; Bumgarner DM; Putnam WC; Miller DK
Life Sci; 2007 Jan; 80(4):337-44. PubMed ID: 17067637
[TBL] [Abstract][Full Text] [Related]
20. Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis.
Santucci V; Storme JJ; Soubrié P; Le Fur G
Life Sci; 1996; 58(6):PL103-10. PubMed ID: 8569415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
